Psychedelics are being decriminalized in several places in the United States. As this occurs, research and development of effective drugs using these once banned substances may increase. That presents a potential powerful investment opportunity for those who are seeking it.

As people seek out new types of medical treatments, the psychedelic companies expand to be able to conduct even more research, which is already proving promising. Research will be tapping into the power of psychedelic mushrooms. Psilocybin, the psycho-active ingredient in psychedelic mushrooms, has the potential to treat serious illnesses such as depression, anxiety, and post-traumatic stress disorder. It might also be effective at the treatment of alcohol and tobacco addictions.
Because of the decriminalization of psychedelics, researchers have been more capable of exploring how psilocybin, could be safely used in health products and associated delivery platforms. R&D work, which is supported by prominent investors, is quickly pushing forward the understanding of the potential of psilocybin. This has allowed some companies to bring products to the market that provide a therapeutic benefit to the consumer.

Over the past five years, a wave of academic research has emerged which supports the notion that psychedelic-inspired medicines are effective and often superior treatments for things like anorexia. In the midst of changing public perception of psychedelics comes better and more advanced research, and investors are always desired. When both legalization and commercialization both occur, we will see a real boom in “magic mushrooms” stocks prices. Hence, the “shroom boom.”
One of the leaders in the push to make mushrooms mainstream and to bring mushroom-infused wellness products to market is Champignon Brands Inc. (CSE: SHRM). This is a rare public company built around research novel molecules. Champignon is focused on the formulation and manufacturing of novel ketamine, anaesthetics, and adaptogenic delivery platforms for nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.

Champignon Brands has been a top-performing new psychedelics IPO. Despite the brutal market conditions the company had to deal with during their inaugural trading week, stocks performed very well with SHRM rising as much as 128% before settling in to close its first week up over 79%.

Investing in the “shroom broom” has the potential to yield some positive results. The net benefit if a solution to drugging up people with depression could revolutionize the way we treat mental disorders. There is also a door wide open to investors looking to cash in on this new medicinal adventure.

Best Regards,

Lior Gantz
President, WealthResearchGroup.com

Disclosure/Disclaimer:
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

Never base any decision off of our emails. Wealth Research Group stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. You should know that Gold Standard Media LLC, owned by the same parties as Wealth Research Group LLC, has been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites.

Please read our full disclaimer at WealthResearchGroup.com/disclaimer